These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16359437)

  • 21. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
    Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
    Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
    McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
    J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
    Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
    BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
    Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
    Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy for prostate cancer.
    Gdor Y; Timme TL; Miles BJ; Kadmon D; Thompson TC
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):309-21. PubMed ID: 12113054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditional Akt activation promotes androgen-independent progression of prostate cancer.
    Li B; Sun A; Youn H; Hong Y; Terranova PF; Thrasher JB; Xu P; Spencer D
    Carcinogenesis; 2007 Mar; 28(3):572-83. PubMed ID: 17032658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
    Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future therapies in hormone-refractory prostate cancer.
    Smith MR; Nelson JB
    Urology; 2005 May; 65(5 Suppl):9-16; discussion 17. PubMed ID: 15885273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.